Emergent BioSolutions（纽约证券交易所代码：EBS）报告的季度每股收益为$0.05，比分析师预期的$(0.49)高出110.2%。 这比去年同期每股亏损$(0.77)增加了106.49%。公司报告的季度销售额为$194.70M，不及分析师预期的$254.67M，低23.55%。 这比去年同期的销售额$276.60M减少了29.61%。
以上内容来自Benzinga Earnings专栏，原文如下：
Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.49) by 110.2 percent. This is a 106.49 percent increase over losses of $(0.77) per share from the same period last year. The company reported quarterly sales of $194.70 million which missed the analyst consensus estimate of $254.67 million by 23.55 percent. This is a 29.61 percent decrease over sales of $276.60 million the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.